CRMP5-IgG-Associated Paraneoplastic Myelopathy with PD-L1 Inhibitor Therapy

Amy Kunchok; Anastasia Zekeridou; Sean Pittock

doi:10.1001/jamaneurol.2019.4379

CRMP5-IgG-Associated Paraneoplastic Myelopathy with PD-L1 Inhibitor Therapy

Amy Kunchok, Anastasia Zekeridou, Sean Pittock

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	255-256
Number of pages	2
Journal	JAMA neurology
Volume	77
Issue number	2
DOIs	https://doi.org/10.1001/jamaneurol.2019.4379
State	Published - Feb 2020

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1001/jamaneurol.2019.4379

Cite this

@article{9bc3fce671904a1b894ce7bb1b78e0c2,

title = "CRMP5-IgG-Associated Paraneoplastic Myelopathy with PD-L1 Inhibitor Therapy",

author = "Amy Kunchok and Anastasia Zekeridou and Sean Pittock",

note = "Funding Information: fees, nonfinancial support, honorarium, and travel expenses for speaking from Alexion Pharmaceuticals and the Guthy-Jackson Charitable Foundation paid to his institution; grants from Grifols, the National Institutes of Health, and Autoimmune Encephalitis Alliance paid to his institution; consulting fees from Euroimmun paid to his institution; and grants, personal fees, nonfinancial support, and honorarium from MedImmune; served on the advisory board of Alexion Pharmaceuticals; holds patent 8,889,102 and 9,891,219B2; and has patents pending for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A.",

year = "2020",

month = feb,

doi = "10.1001/jamaneurol.2019.4379",

language = "English (US)",

volume = "77",

pages = "255--256",

journal = "JAMA neurology",

issn = "2168-6149",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - CRMP5-IgG-Associated Paraneoplastic Myelopathy with PD-L1 Inhibitor Therapy

AU - Kunchok, Amy

AU - Zekeridou, Anastasia

AU - Pittock, Sean

N1 - Funding Information: fees, nonfinancial support, honorarium, and travel expenses for speaking from Alexion Pharmaceuticals and the Guthy-Jackson Charitable Foundation paid to his institution; grants from Grifols, the National Institutes of Health, and Autoimmune Encephalitis Alliance paid to his institution; consulting fees from Euroimmun paid to his institution; and grants, personal fees, nonfinancial support, and honorarium from MedImmune; served on the advisory board of Alexion Pharmaceuticals; holds patent 8,889,102 and 9,891,219B2; and has patents pending for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A.

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85076818402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076818402&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2019.4379

DO - 10.1001/jamaneurol.2019.4379

M3 - Comment/debate

C2 - 31860013

AN - SCOPUS:85076818402

SN - 2168-6149

VL - 77

SP - 255

EP - 256

JO - JAMA neurology

JF - JAMA neurology

IS - 2

ER -

CRMP5-IgG-Associated Paraneoplastic Myelopathy with PD-L1 Inhibitor Therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this